Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;34(8):4201-5.

Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

Shoichi Hazama  1 , Hiroko Takenouchi  2 , Ryouichi Tsunedomi  2 , Michihisa Iida  2 , Nobuaki Suzuki  2 , Norio Iizuka  2 , Yuka Inoue  2 , Kazuhiko Sakamoto  2 , Mitsuhiro Nakao  2 , Yoshitaro Shindo  2 , Shinsuke Kanekiyo  2 , Yukio Tokumitsu  2 , Kiyoshi Yoshimura  2 , Noriko Maeda  2 , Kazunari Maeda  2 , Yoshinari Maeda  2 , Hiroto Matsui  2 , Shigefumi Yoshino  2 , Yusuke Nakamura  3 , Yusuke Fujita  4 , Yoshihiko Hamamoto  4 , Masato Okamoto  5 , Tomonobu Fujita  5 , Yutaka Kawakami  5 , Masaaki Oka  2
Affiliations
  • PMID: 25075047

Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

Shoichi Hazama et al. Anticancer Res. 2014 Aug.

Abstract

Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A*2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy.

Patients and methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides.

Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction.

Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.

Keywords: Predictive biomarker; colorectal cancer; peptide vaccine; prognosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources